Immunotherapy
-
The treatment of non-small-cell lung cancer has changed after the development of the immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its clinical significance is still debatable. In this article, we show the updated survival analysis of all published data. ⋯ PD-L1 overexpression predicts activity as well as better survival for patients treated with immune checkpoint inhibitors.